Health Economics›Chronic lymphocytic leukemia›First-line therapy

First-line therapy

Chronic lymphocytic leukemia · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Idelalisib and Rituximab Variant #02 Partial	—	R 129 524	28d	~12.6 mo	—	~18	~R 207 238 PFS proxy · indirect	2
R-FCM Variant #01	—	R 67 954	28d	—	—	~6	~R 252 295 indirect	—
Cladribine and Prednisone Variant #01	—	R 55 441	28d	—	—	~4	~R 221 765 indirect	—
Fludarabine and Rituximab (FR) Variant #01	—	R 34 157	28d	—	—	~6	~R 204 943 indirect	—
Fludarabine and Prednisone Variant #01	—	R 27 519	28d	—	—	~2	~R 55 037 indirect	—
CMC Variant #01	—	R 23 789	28d	—	—	~6	~R 142 733 indirect	—
FCM Variant #01	—	R 16 144	28d	—	—	~6	~R 96 867 indirect	—
miniCHOP-F Variant #01	—	R 14 589	30d	—	—	~3	~R 43 767 indirect	—
Cyclophosphamide and Fludarabine (FC) Variant #15	—	R 14 005	—	31.6 mo	—	8	R 112 036 PFS proxy	1
Fludarabine monotherapy Variant #05	—	R 13 754	28d	23.3 mo	52.9 mo	8	R 110 032 PFS proxy	2
Chlorambucil monotherapy Variant #03	—	R 2 355	28d	12.6 mo	—	13	R 30 610 PFS proxy	5
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	30.8 mo	—	13	R 28 314 PFS proxy	1
Chlorambucil and Prednisone Variant #01	—	R 1 276	30d	—	—	~36	~R 45 921 indirect	—
CHOP Variant #20	—	R 835	21d	~15.5 mo	—	~6	~R 5 011 PFS proxy · indirect	4
CAP Variant #01	—	R 709	30d	—	—	~6	~R 4 256 indirect	—
CVP Variant #01	—	R 613	21d	—	—	~8	~R 4 901 indirect	—
Uracil mustard monotherapy Partial	—	—	—	—	—	—	—	—

17 of 17 regimens shown